To prescribe or not: a two-center retrospective observational study of antibiotics usage and outcomes of COVID-19 in Turkey.

Publication date: Sep 09, 2024

This retrospective cohort study conducted in Turkey between December 2020 and June 2022 aimed to assess antibiotic use, bacterial co-infections, and the associated factors on mortality in hospitalized patients with mild-to-severe COVID-19. Among the 445 patients, 80% received antibiotics, with fluoroquinolones being the most common choice, followed by beta-lactams and combinations. Various clinical and laboratory parameters, including symptoms, comorbidities, CCI, oxygen requirements, and CRP levels were observed to be elevated in the antibiotic group. Non-survivors had more ICU admissions and longer hospital stays compared to survivors. We conducted a multivariate Cox regression analysis to evaluate factors related to mortality. However, we did not find an association between antibiotic use and mortality [HR 2. 7 (95% CI 0. 4-20)]. The study identified significant factors associated with an antibiotic prescription, such as CCI (OR 1. 6), CRP (OR 2. 3), and ICU admission (OR 8. 8), (p 

Open Access PDF

Concepts Keywords
Antibiotics Adult
December Aged
June Anti-Bacterial Agents
Mortality Anti-Bacterial Agents
Turkey Antibiotic usage
Bacterial co-infections
Bacterial Infections
Coinfection
COVID-19
COVID-19
COVID-19 Drug Treatment
Female
Humans
Intensive Care Units
Male
Middle Aged
Mortality
Retrospective Studies
SARS-CoV-2
SARS-CoV-2
Treatment Outcome
Turkey

Semantics

Type Source Name
disease MESH COVID-19
disease MESH co-infections
drug DRUGBANK Oxygen
drug DRUGBANK Coenzyme M
disease MESH infections
disease MESH bacterial infections
disease MESH viral disease
disease MESH morbidity
disease MESH influenza
disease MESH pneumonia
disease MESH Infectious Diseases
disease MESH complications
disease MESH Clostridium difficile infections
disease MESH renal failure
disease IDO bacteria
disease MESH drug toxicities
disease MESH drug interactions
drug DRUGBANK Methionine
disease MESH lymphopenia
disease MESH malignancy
disease MESH hypertension
disease IDO history
disease MESH COPD
disease MESH diabetes mellitus
disease IDO immunosuppression
disease MESH death
disease IDO blood
drug DRUGBANK Creatinine
disease IDO infection
disease MESH Comorbidity
drug DRUGBANK Favipiravir
drug DRUGBANK Lopinavir
drug DRUGBANK Ritonavir
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Tocilizumab
drug DRUGBANK Anakinra
drug DRUGBANK Immune Globulin Human
drug DRUGBANK Linezolid
drug DRUGBANK Colistin
drug DRUGBANK Azithromycin
disease IDO symptom
disease MESH sore throat
disease MESH arthralgia
drug DRUGBANK Trestolone
drug DRUGBANK Moxifloxacin
drug DRUGBANK Levofloxacin
drug DRUGBANK Ciprofloxacin
disease MESH Chest pain
disease MESH uncertainty
disease MESH bacterial pneumonia
drug DRUGBANK Cefaclor
disease IDO country
drug DRUGBANK Medical air
disease MESH respiratory tract infections
disease MESH critically ill
disease MESH abnormalities
disease IDO susceptibility
disease IDO secondary infection
disease IDO antibiotic resistance
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)